[ad_1]
Researchers have developed a new insulin molecule that responds to blood sugar glucose levels in rats, which they believe could help patients with type 1 diabetes.
Researchers have developed a glucose reactive insulin molecule (GRI) that they believe could revolutionize treatment for type 1 diabetes. The study was conducted at the University of Copenhagen, Denmark, and the biotech company Gubra.
According to the team, insulin on the market today cannot identify whether a patient with type 1 diabetes needs a small or large effect from insulin, which lowers blood sugar.
“That’s why we have developed the first step towards a type of insulin that can self-regulate based on the patient’s blood sugar level. This has enormous potential to greatly improve the lives of people with type 1 diabetes, ‘explained Professor Knud Jensen, one of the researchers.
Researchers developed cleavable glucose linkers based on hydrazone and thiazolidine structures. They created linkers with low levels of spontaneous hydrolysis but increased levels of hydrolysis with increasing concentrations of glucose, allowing them to sense how much glucose is in the body. Although you constantly release some insulin, as your blood sugar rises, the molecule becomes more active and releases more insulin. When blood sugar falls, less is released. By testing the molecule on rats, the researchers found that it was effective.
Researchers explain that lipidated hydrazones and thiazolidines were conjugated to HI’s LysB29 side chain by pH controlled acylations that provide GRIs with a confirmed glucose response. in vitro for thiazolidines. Studies with the clamp showed an increase in glucose infusion under hyperglycemic conditions for a GRI indicative of a true glucose response.
The glucose-reactive splittable linker in these GRIs allowed changes in glucose levels to drive the release of active insulin.
“It will provide patients with type 1 diabetes with safer and easier treatment. Today, a person with type 1 diabetes has to inject insulin many times throughout the day and frequently monitor their blood sugar level by pricking their finger with a blood glucose meter. This here, allows a person to inject the new insulin molecule less often throughout the day and therefore think about it less, ”Jensen said.
The results were published in Chemistry Europe.
Source link
